USA flag logo/image

An Official Website of the United States Government

Microfluidic DNA Sequencing

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96279
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HG005144
Solicitation Year:
N/A
Solicitation Topic Code:
NHGRI
Solicitation Number:
N/A
Small Business Information
GNUBIO, INC.
1 Kendall Square Cambridge, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Microfluidic DNA Sequencing
Agency: HHS
Contract: 1R43HG005144-01
Award Amount: $240,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Most next-generation DNA sequencing methods have focused on either 1) template amplification followed by massively-parallel sequencing-by-synthesis, or 2) single molecule detection. The first method is now commercially available but suffers from relatively large volumes of expensive reagent usage. The latter method, although not yet commercially available, will have a disadvantage in signal-to-noise and therefore require more sensitive and expensive instrumentation. To avoid these disadvantages, we will use droplet-based microfluidics to sequence DNA. By using microfluidics we limit the amount of reagent required to sequence DNA to less than several milliliters, while still retaining the ability to amplify the template t hat thereby enables us to use relatively inexpensive and robust detection. Hybridization of short probes will be detected in microfluidic droplets by a shift in fluorescence polarization that distinguishes between bound and free oligo. This removes the req uirement for a separation phase to detect hybridization. The method is simple and does not require enzymes. In Phase I we will describe a simple platform and resequencing method that will be scaled in a future Phase II project to enable human genome sequen cing for under 1000. Public Health Relevance: The proposed Phase I droplet-based microfluidics instrument will generate, selectively merge and analyze over 10,000 aqueous droplets per second. We want to leverage this capability to implement a DN A sequencing method on a microfluidics platform. We have broken the project up into two phases. Phase I is proof of principle. In Phase I we demonstrate that the biochemical assay works in drops and also that our detector works. In Phase II we will scale the process to build a machine that will be able to sequence a human genome for less than 1000.

Principal Investigator:

Adam R. Abate

Business Contact:

Small Business Information at Submission:

GNUBIO, INC.
GNUBIO, INC. 35 TWIN DIAMOND DR BRIDGEWATER, MA 02324

EIN/Tax ID: 127147415
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No